modelR01AD03
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Dexamethasone | |
| ATC code: | R01AD03 | route: | intranasal |
| compartments: | 1 | |
| dosage: | 1 | mg |
| volume of distribution: | 1.53 | L |
| clearance: | 0.114 | L/hr/kg |
| other parameters in model implementation | ||
Dexamethasone is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressant effects. It is used for the treatment of various conditions including allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, and respiratory diseases. Dexamethasone is approved for use and is listed by the WHO as an essential medicine. In the context of the ATC code R01AD03, it is used as a nasal preparation for the treatment of nasal inflammation and allergic rhinitis.
Pharmacokinetics
Pharmacokinetic parameters in healthy adult volunteers after intranasal administration.
References
Edwards, TB (1995). Effectiveness and safety of beclomethasone dipropionate, an intranasal corticosteroid, in the treatment of patients with allergic rhinitis. Clinical therapeutics 17(6) 1032–1041. DOI:10.1016/0149-2918(95)80082-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8750396
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)